Iron overload
Iron overload | |
---|---|
Other names | Haemochromatosis or Hemochromatosis |
Micrograph
of liver Iron stain. | |
Specialty | Hematology, gastroenterology/hepatology |
Iron overload (also haemochromatosis (
Signs and symptoms
Organs most commonly affected by hemochromatosis include the liver, heart, and endocrine glands.[3]
Hemochromatosis may present with the following clinical syndromes:
- liver: chronic liver disease and cirrhosis of the liver.[4]
- heart: cardiac arrhythmia.[4]
- hormones: diabetes (see below) and hypogonadism (insufficiency of the sex hormone producing glands) which leads to low sex drive and/or loss of fertility in men and loss of fertility and menstrual cycle in women.[4]
- metabolism:
- skeletal: radiocarpal joints, elbow, hip, knee and ankle joints.[6][7] Risk factors for the development of arthritis in those with hemochromatosis include elevated iron levels (ferritin greater than 1000 or transferrin saturation greater than 50%) for an extended period of time, increasing age and concurrent advanced liver fibrosis.[6]
- skin: melanoderma (darkening or 'bronzing' of the skin).[7][8]
Hemochromatosis leading to secondary diabetes (through iron deposition in the insulin secreting beta cells of the pancreas), when combined with a bronzing or darkening of the skin, is sometimes known as "bronze diabetes".[9]
Causes
The term hemochromatosis was initially used to refer to what is now more specifically called
Primary hemochromatosis and hemosiderosis
Hereditary hemochromatosis
Hereditary hemochromatosis is an autosomal recessive disorder with estimated prevalence in the population of 1 in 200 among patients with European ancestry, with lower incidence in other ethnic groups.
Hereditary hemochromatosis is characterized by an accelerated rate of intestinal iron absorption and progressive iron deposition in various tissues. This typically begins to be expressed in the third to fifth decades of life, but may occur in children. The most common presentation is hepatic cirrhosis in combination with hypopituitarism, cardiomyopathy, diabetes, arthritis, or hyperpigmentation. Because of the severe sequelae of this disorder if left untreated, and recognizing that treatment is relatively simple, early diagnosis before symptoms or signs appear is important.[14][15]
Hemosiderosis
In general, the term is used instead.
Other definitions distinguishing hemochromatosis or hemosiderosis that are occasionally used include:
- Hemosiderosis is hemochromatosis caused by excessive blood transfusions, that is, hemosiderosis is a form of secondary hemochromatosis.[18][19]
- Hemosiderosis is hemosiderin deposition within cells, while hemochromatosis is hemosiderin within cells and interstitium.[20]
- Hemosiderosis is iron overload that does not cause tissue damage,[21] while hemochromatosis does.[22]
- Hemosiderosis is arbitrarily differentiated from hemochromatosis by the reversible nature of the iron accumulation in the reticuloendothelial system.[23]
The causes of hemochromatosis broken down into two subcategories: primary cases (hereditary or genetically determined) and less frequent secondary cases (acquired during life).[24] People of Northern European descent, including Celtic (Irish, Scottish, Welsh, Cornish, Breton etc.), English, and Scandinavian origin[25] have a particularly high incidence, with about 10% being carriers of the principal genetic variant, the C282Y mutation on the HFE gene, and 1% having the condition.[26]
Non-classical hereditary hemochromatosis
The overwhelming majority depend on mutations of the HFE gene discovered in 1996, but since then others have been discovered and sometimes are grouped together as "non-classical hereditary hemochromatosis",[27] "non-HFE related hereditary hemochromatosis",[28] or "non-HFE hemochromatosis".[29]
Description | OMIM |
Mutation |
Hemochromatosis type 1 : "classical" hemochromatosis |
235200 | HFE |
Hemochromatosis type 2A : juvenile hemochromatosis |
602390 | Haemojuvelin (HJV, also known as RGMc and HFE2) |
Hemochromatosis type 2B : juvenile hemochromatosis |
606464 | hepcidin antimicrobial peptide ( HAMP ) or HFE2B
|
Hemochromatosis type 3 | 604250 | transferrin receptor-2 (TFR2 or HFE3)
|
Hemochromatosis type 4 / African iron overload |
604653 | ferroportin (SLC11A3/SLC40A1) |
Neonatal hemochromatosis |
231100 | (unknown) |
Acaeruloplasminaemia (very rare) | 604290 | caeruloplasmin
|
Congenital atransferrinaemia (very rare) |
209300 | transferrin |
GRACILE syndrome (very rare) | 603358 | BCS1L |
Most types of hereditary hemochromatosis have
Secondary hemochromatosis
- Severe chronic hemolysis of any cause, including intravascular hemolysis and ineffective erythropoiesis (hemolysis within the bone marrow)
- Multiple frequent Diamond–Blackfan anaemia) or by older patients with severe acquired anaemias such as in myelodysplastic syndromes.[5]
- Excess parenteral (non-ingested) iron supplements, such as what can acutely happen in iron poisoning
- Excess dietary iron
- Some disorders do not normally cause hemochromatosis on their own, but may do so in the presence of other predisposing factors. These include hemodialysis, and post-portacaval shunting
Pathophysiology
Defects in iron metabolism, specifically involving the iron regulatory protein hepcidin are thought to play an integral role in the pathogenesis of hereditary hemochromatosis.[6]
Normally, hepcidin acts to reduce iron levels in the body by inhibiting intestinal iron absorption and inhibiting iron mobilization from stores in the bone marrow and liver.[6] Iron is absorbed from the intestines (mostly in the duodenum) and transported across intestinal enterocytes or mobilized out of storage in liver hepatocytes or from macrophages in the bone marrow by the transmembrane ferroportin transporter.[6] In response to elevated plasma iron levels, hepcidin inhibits the ferroportin transporter leading to decreased iron mobilization from stores and decreased intestinal iron absorption, thus functioning as a negative iron regulatory protein.[6]
In hereditary hemochromatosis, mutations in the proteins involved in hepcidin production including HFE (hemostatic iron regulator), hemojuvelin and transferrin receptor 2 lead to a loss or decrease in hepcidin production, which subsequently leads to the loss of the inhibitory signal regulating iron absorption and mobilization and thus leads to iron overload.[6] In very rare instances, mutations in ferroportin result in ferroportin resistance to hepcidin's negative regulatory effects, and continued intestinal iron absorption and mobilization despite inhibitory signaling from hepcidin.[6] Approximately 95% of cases of hereditary hemochromatosis are due to mutations in the HFE gene.[6]
The resulting iron overload causes iron to deposit in various sites throughout the body, especially the liver and joints, which coupled with oxidative stress leads to organ damage or joint damage and the pathological findings seen in hemochromatosis.[6]
Diagnosis
There are several methods available for diagnosing and monitoring iron overload.
Blood test
Blood tests are usually the initial test if there is a clinical suspicion of iron overload. Serum
Elevations in serum levels of the iron transporter protein
Genetics
General screening for hemochromatosis is not recommended, however
Once iron overload has been established,
Biopsy
Liver biopsy is the removal of small sample in order to be studied and can determine the cause of inflammation or cirrhosis. In someone with negative HFE gene testing, elevated iron status for no other obvious reason, and family history of liver disease, additional evaluation of liver iron concentration is indicated. In this case, diagnosis of hemochromatosis is based on biochemical analysis and histologic examination of a liver biopsy. Assessment of the hepatic iron index (HII) is considered the "gold standard" for diagnosis of hemochromatosis.[citation needed]
Imaging
Magnetic resonance imaging (MRI) is used as a noninvasive method to estimate iron deposition levels in the liver and heart, which may aid in determining a response to treatment or prognosis.[6] Liver elastography has limited utility in detecting liver fibrosis in hemochromatosis.[6]
Treatment
Phlebotomy
Phlebotomy is associated with improved survival if it is initiated before the onset of cirrhosis or diabetes.[38]
Diet
The human diet contains iron in two forms: heme iron and non-heme iron. Heme iron is usually found in red meat, whereas non-heme iron is found in plant based sources. Heme iron is the most easily absorbed form of iron. In those with hemochromatosis undergoing phlebotomy for treatment; restriction of dietary iron is not required.[38][39][6] However, those who do restrict dietary iron usually require less blood needing to be phlebotomized (about 0.5-1.5 liters of blood less per year).[43] Vitamin C and iron supplementation should be avoided as vitamin C accelerates intestinal absorption of iron and mobilization of body iron stores.[38][39] Raw seafood should be avoided because of increased risk of infections from iron loving pathogens such as Vibrio vulnificus.[6][44] Alcohol consumption should be avoided due to the risk of compounded liver damage with iron overload.[6]
Medication
Medications are used for those unable to tolerate routine blood draws, there are
Chelating polymers
A minimally invasive approach to hereditary hemochromatosis treatment is the maintenance therapy with polymeric chelators.[48][49][50] These polymers or particles have a negligible or null systemic biological availability and they are designed to form stable complexes with Fe2+ and Fe3+ in the GIT and thus limiting their uptake and long-term accumulation. Although this method has only a limited efficacy, unlike small-molecular chelators, the approach has virtually no side effects in sub-chronic studies.[50] Interestingly, the simultaneous chelation of Fe2+ and Fe3+ increases the treatment efficacy.[50]
Prognosis
In general, provided there has been no liver damage, patients should expect a normal life expectancy if adequately treated by venesection. If the serum ferritin is greater than 1,000 µg/L at diagnosis there is a risk of liver damage and cirrhosis which may eventually shorten their life.[51] The presence of cirrhosis increases the risk of hepatocellular carcinoma.[52] Other risk factors for liver damage in hemochromatosis include alcohol use, diabetes, liver iron levels greater than 2,000 μmol/gram and increased aspartate transaminase levels.[6]
The risk of death and liver fibrosis are elevated in males with HFE type hemochromatosis but not in females; this is thought to be due to a protective effect of menstruation and pregnancy seen in females as well as possible hormone-related differences in iron absorption.[6]
Epidemiology
HHC is most common in certain European populations (such as those of Irish or Scandinavian descent) and occurs in 0.6% of some unspecified population.[37] Men have a 24-fold increased rate of iron-overload disease compared with women.[37]
Stone Age
Diet and the environment are thought to have had large influence on the mutation of genes related to iron overload. Starting during the
Neolithic
In the
Viking hypothesis
Studies and surveys conducted to determine the frequencies of hemochromatosis help explain how the mutation migrated around the globe. In theory, the disease initially evolved from travelers migrating from the north. Surveys show a particular distribution pattern with large clusters and frequencies of gene mutations along the western European coastline.
Modern times
In 1865, Armand Trousseau (a French internist) was one of the first to describe many of the symptoms of a diabetic patient with cirrhosis of the liver and bronzed skin color. The term hemochromatosis was first used by German pathologist Friedrich Daniel von Recklinghausen in 1889 when he described an accumulation of iron in body tissues.[59]
Identification of genetic factors
Although it was known most of the 20th century that most cases of hemochromatosis were inherited, they were incorrectly assumed to depend on a single gene.[60]
In 1935 J.H. Sheldon, a British physician, described the link to iron metabolism for the first time as well as demonstrating its hereditary nature.[59]
In 1996 Felder and colleagues identified the hemochromatosis gene, HFE gene. Felder found that the HFE gene has two main mutations, causing amino acid substitutions C282Y and H63D, which were the main cause of hereditary hemochromatosis.[59][61] The next year the CDC and the National Human Genome Research Institute sponsored an examination of hemochromatosis following the discovery of the HFE gene, which helped lead to the population screenings and estimates that are still being used today.[62]
See also
References
- ^ PMID 35699322.
- PMID 24470094.
- PMID 10607817.
- ^ ISBN 978-0-07-470436-3.[page needed]
- ^ S2CID 25357672.
- ^ S2CID 254432917.
- ^ a b Bruce R Bacon, Stanley L Schrier. "Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)". UpToDate. Retrieved 2016-07-14. Literature review current through: Jun 2016. | This topic last updated: Apr 14, 2015.
- PMID 29620054.
- ^ "Haemochromatosis and diabetes". Diabetes UK.
- ^ thefreedictionary.com > hemochromatosis, citing:
- The American Heritage Medical Dictionary, 2004 by Houghton Mifflin Company
- McGraw-Hill Concise Dictionary of Modern Medicine. 2002
- ^ Merriam-Webster's Medical Dictionary > hemochromatosis Retrieved on December 11, 2009
- ^ thefreedictionary.com, citing:
- Dorland's Medical Dictionary for Health Consumers, 2007
- Mosby's Medical Dictionary, 8th edition. 2009
- Jonas: Mosby's Dictionary of Complementary and Alternative Medicine. 2005.
- ^ "Hemochromatosis". Archived from the original on 2007-03-18. Retrieved 2012-10-05.
- ^ PMID 20542038.
- PMID 10488796.
- ^ Merriam-Webster's Medical Dictionary > hemosideroses Retrieved on December 11, 2009
- ^ thefreedictionary.com > hemosiderosis, citing:
- The American Heritage Medical Dictionary, 2004 by Houghton Mifflin Company
- Mosby's Medical Dictionary, 8th edition.
- ^ eMedicine Specialties > Radiology > Gastrointestinal > Hemochromatosis Author: Sandor Joffe, MD. Updated: May 8, 2009
- ^ thefreedictionary.com > hemosiderosis, citing:
- Gale Encyclopedia of Medicine. Copyright 2008
- ^ Notecards on radiology gamuts, diseases, anatomy Archived 2010-07-21 at the Wayback Machine 2002, Charles E. Kahn, Jr., MD. Medical College of Wisconsin
- ^ thefreedictionary.com > hemosiderosis, citing:
- Dorland's Medical Dictionary for Health Consumers, 2007
- Mosby's Dental Dictionary, 2nd edition.
- Saunders Comprehensive Veterinary Dictionary, 3rd ed. 2007
- ^ The HealthScout Network > Health Encyclopedia > Diseases and Conditions > Hemochromatosis Archived 2010-02-09 at the Wayback Machine Retrieved on December 11, 2009
- ^ thefreedictionary.com > hemosiderosis, citing:
- McGraw-Hill Concise Dictionary of Modern Medicine. 2002
- PMID 12651879.
- ^ The Atlantic: "The Iron in Our Blood That Keeps and Kills Us" by Bradley Wertheim January 10, 2013
- ^ "Hemachromatosis". Encyclopædia Britannica.com. Retrieved 17 April 2017.
- S2CID 23206256.
- ISBN 978-0-7817-6040-9.
- S2CID 260320984.
- PMID 16493621.
- PMID 18025154.
- S2CID 44923011.
- ^ a b Ferritin by: Mark Levin, MD, Hematologist and Oncologist, Newark, NJ. Review provided by VeriMed Healthcare Network
- ^ a b Andrea Duchini. "Hemochromatosis Workup". Medscape. Retrieved 2016-07-14. Updated: Jan 02, 2016
- ^ a b Molar concentration is derived from mass value using molar mass of 450,000 g•mol−1 for ferritin
- ^ labtestsonline.org TIBC & UIBC, Transferrin Last reviewed on October 28, 2009.
- ^ PMID 23418762.
- ^ S2CID 9311604.
- ^ S2CID 198192589.
- PMID 17729397.
- S2CID 53087679.
- ^ NIH blood bank. "Hemochromatosis Donor Program".
- PMID 23803887.
- PMID 1872665.
- .
- S2CID 19930076.
- PMID 12637334.
- PMID 16283713.
- PMID 35610854.
- ^ S2CID 221827050.
- PMID 18199861.
- PMID 15508107.
- ^ "The Evolution of Diet". National Geographic. Retrieved 2018-04-11.
- PMID 10198751.
- ^
Heath KM, Axton JH, McCullough JM, Harris N (May 2016). "The evolutionary adaptation of the C282Y mutation to culture and climate during the European Neolithic". American Journal of Physical Anthropology. 160 (1): 86–101. PMID 26799452.
- ^ "Clinical Penetrance of HFE Hereditary Hemochromatosis, Serum Ferritin Levels, and Screening Implications: Can We Iron This Out?". www.hematology.org. 2008-05-01. Archived from the original on 2018-06-15. Retrieved 2018-04-11.
- PMID 21766093.
- ^ "Videos: Hereditary Hemochromatosis | Canadian Hemochromatosis Society". www.toomuchiron.ca. Retrieved 2018-04-11.
- ^ PMID 29663319.
- ISBN 978-1-58829-202-5.
- S2CID 26239768.
- PMID 9669792.